Vitamins & Nutrition · LP-171
Retinol (Vitamin A) Capsules
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-171Vitamins & Nutrition
- Generic identity
- Retinol (Vitamin A)Capsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-171
- Generic ingredient
- Retinol (Vitamin A)
- Dosage form
- Capsule
- Proposed strength
- 100,000 IU; 200,000 IU
- Proposed pack
- Soft capsule; bottle or blister
- Portfolio category
- Vitamins & Nutrition
About Retinol (Vitamin A)
Retinol is preformed vitamin A, a fat-soluble nutrient involved in vision, immunity and cellular development. It can accumulate in the body, and concentrated medicinal presentations require a clearly defined indication. The catalogue includes high-strength capsules and concentrated oral drops. These are not ordinary unrestricted daily multivitamins, and their strengths must not be converted into a self-treatment schedule from this website.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Vitamin A use may form part of deficiency treatment or a defined public-health programme in populations where the benefit-risk balance supports it. Eligibility depends on age, pregnancy and clinical or programme criteria. A capsule programme cannot automatically be translated into drop-based administration. Nutritional status, diet and other retinoid exposure matter. No WHO prequalification, programme eligibility or exact approved population is established by listing retinol in the catalogue.
Important safety considerations
Excess preformed vitamin A can cause significant toxicity, including liver, neurological and bone effects. Pregnancy exposure can harm the fetus, so pregnancy possibility and concurrent retinoid medicines require particular review. Headache, vomiting, visual changes or other toxicity symptoms need assessment. Children are vulnerable to errors with concentrated products. Total intake from supplements, medicines and diet must be considered, and vitamin A should not be presented as harmless because it is a nutrient.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
Capsules and concentrated drops are separate presentations. The vitamin A ester, strength basis and measuring device must be verified. A drop volume is not standardized across droppers; no drops-to-units conversion can be inferred from the catalogue.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm deficiency or programme rationale, patient age, pregnancy risk, liver status and other vitamin A or retinoid exposure. Verify the exact formulation and measurement system.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Retinol (Vitamin A)
- Dosage form / presentation
- Capsule
- Catalogue strength
- 100,000 IU; 200,000 IU
- Catalogue pack
- Soft capsule; bottle or blister
- Portfolio category
- Vitamins & Nutrition
Layer 02
Unresolved product-specific fields
- The catalogue lists high-strength retinol capsules at 100,000 IU and 200,000 IU. It does not identify the retinol ester, IU strength basis, capsule composition or patient group.
- Capsule and oral-drop records are separate. No conversion between IU, retinol activity equivalents or drop quantities is asserted without exact formulation evidence.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Vitamin A and Carotenoids — Health Professional Fact Sheetgovernment scientific fact sheet
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled capsule specification confirming retinol form/ester, IU strength basis, capsule composition and exact pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-171, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-171.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.